A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
NCT ID: NCT05579925
Last Updated: 2024-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
24 participants
INTERVENTIONAL
2022-10-07
2023-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis
NCT06162507
Study of CM310 in Adolescent Subjects With Atopic Dermatis
NCT06495229
A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
NCT05265923
Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis
NCT06277765
A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT06116565
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CM310
600 mg + 300 mg, subcutaneous injection, once every two weeks
CM310
CM310 600 mg + 300 mg, subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CM310
CM310 600 mg + 300 mg, subcutaneous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With atopic dermatis
* Voluntarily sign the informed consent form
Exclusion Criteria
* Major surgery planed during the study
12 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Keymed Biosciences Co.Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Children's Hospital Capital Medical University
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CM310-101108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.